Translating NCCN Guidelines speaks directly to the NCCN mission of making NCCN Content accessible to providers and patients globally. As a result, NCCN works to translate the NCCN Guidelines into multiple languages and publishes these important resources on NCCN.org as well as within NCCN mobile application for free so that they may be accessed by clinicians around the world.
Breast Cancer Version 4.2023 (Arabic)
Colon Cancer Version 3.2021 (Arabic)
Multiple Myeloma Version 5.2022 (Arabic)
Non-Small Cell Lung Cancer Version 7.2024 (Arabic)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Arabic)
Acute Lymphoblastic Leukemia Version 1.2022 (Chinese)
Acute Myeloid Leukemia Version 2.2022 (Chinese)
Adolescent and Young Adult (AYA) Oncology Version 1.2024 (Chinese)
Adult Cancer Pain Version 2.2024 (Chinese)
B-Cell Lymphomas Version 5.2022 (Chinese)
Bladder Cancer Version 2.2022 (Chinese)
Breast Cancer Version 4.2022 (Chinese)
Central Nervous System Cancers Version 3.2024 (Chinese)
Cervical Cancer Version 1.2022 (Chinese)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2023 (Chinese)
Colon Cancer Version 1.2022 (Chinese)
Esophageal and Esophagogastric Junction Cancers Version 3.2022 (Chinese)
Gastric Cancer Version 2.2022 (Chinese)
Gestational Trophoblastic Neoplasia Version 1.2022 (Chinese)
Hairy Cell Leukemia Version 1.2021 (Chinese)
Head and Neck Cancers Version 2.2022 (Chinese)
Hepatobiliary Cancers Version 4.2022 (Chinese)
Hodgkin Lymphoma Version 4.2021 (Chinese)
Melanoma: Cutaneous Version 2.2023 (Chinese)
Multiple Myeloma Version 2.2024 (Chinese)
Myelodysplastic Syndromes Version 1.2023 (Chinese)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Chinese)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Chinese)
Primary Cutaneous Lymphomas Version 2.2022 (Chinese)
Prostate Cancer Version 4.2022 (Chinese)
Small Cell Lung Cancer Version 1.2023 (Chinese)
T-Cell Lymphomas Version 1.2021 (Chinese)
Uterine Neoplasms Version 1.2022 (Chinese)
Vulvar Cancer Version 1.2022 (Chinese)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (Chinese)
Acute Lymphoblastic Leukemia Version 1.2022 (French)
Breast Cancer Version 8.2021 (French)
Colon Cancer Version 3.2021 (French)
Multiple Myeloma Version 5.2022 (French)
Non-Small Cell Lung Cancer Version 3.2022 (French)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (French)
T-Cell Lymphomas Version 2.2022 (French)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (French)
Multiple Myeloma Version 5.2022 (German)
T-Cell Lymphomas Version 2.2022 (German)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (German)
Acute Lymphoblastic Leukemia Version 4.2021 (Italian)
Breast Cancer Version 4.2024 (Italian)
Hairy Cell Leukemia Version 1.2021 (Italian)
Hepatocellular Carcinoma Version 2.2024 (Italian)
Hodgkin Lymphoma Version 4.2021 (Italian)
Multiple Myeloma Version 5.2022 (Italian)
Non-Small Cell Lung Cancer Version 3.2023 (Italian)
Pediatric Acute Lymphoblastic Leukemia Version 1.2022 (Italian)
Primary Cutaneous Lymphomas Version 2.2022 (Italian)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (Italian)
Acute Lymphoblastic Leukemia Version 1.2022 (Japanese)
Kidney Cancer Version 1.2021 (Japanese)
Multiple Myeloma Version 5.2022 (Japanese)
Non-Small Cell Lung Cancer Version 3.2023 (Japanese)
Pancreatic Adenocarcinoma Version 2.2021 (Japanese)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (Japanese)
Colon Cancer Version 1.2022 (Korean)
Multiple Myeloma Version 5.2022 (Korean)
Non-Small Cell Lung Cancer Version 3.2022 (Korean)
Colon Cancer Version 3.2021 (Polish)
Multiple Myeloma Version 1.2023 (Polish)
Non-Small Cell Lung Cancer Version 1.2021 (Polish)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Polish)
Acute Myeloid Leukemia Version 2.2022 (Portuguese - Latin America Editions)
B-Cell Lymphomas Version 4.2022 (Portuguese)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2023 (Portuguese)
Colon Cancer Version 3.2021 (Portuguese)
Head and Neck Cancers Version 2.2023 (Portuguese)
Hepatocellular Carcinoma Version 2.2024 (Portuguese)
Multiple Myeloma Version 3.2023 (Portuguese - Latin America Editions)
Myelodysplastic Syndromes Version 1.2023 (Portuguese)
Non-Small Cell Lung Cancer Version 7.2024 (Portuguese)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Portuguese)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Portuguese)
Prostate Cancer Version 2.2021 (Portuguese)
Small Cell Lung Cancer Version 3.2024 (Portuguese)
T-Cell Lymphomas Version 2.2022 (Portuguese)
Colon Cancer Version 1.2022 (Romanian)
Multiple Myeloma Version 1.2023 (Romanian)
Non-Small Cell Lung Cancer Version 3.2023 (Romanian)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Romanian)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (Romanian)
Multiple Myeloma Version 1.2023 (Russian)
Pediatric Acute Lymphoblastic Leukemia Version 1.2021 (Russian)
Acute Lymphoblastic Leukemia Version 1.2022 (Spanish)
Acute Myeloid Leukemia Version 3.2023 (Spanish - Latin America Editions)
Breast Cancer Version 2.2022 (Spanish)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2023 (Spanish)
Colon Cancer Version 3.2021 (Spanish)
Hairy Cell Leukemia Version 1.2021 (Spanish)
Head and Neck Cancers Version 4.2024 (Spanish)
Hepatocellular Carcinoma Version 2.2024 (Spanish)
Hodgkin Lymphoma Version 1.2023 (Spanish)
Melanoma: Cutaneous Version 2.2024 (Spanish)
Multiple Myeloma Version 5.2022 (Spanish - European Editions)
Multiple Myeloma Version 3.2023 (Spanish - Latin America Editions)
Myelodysplastic Syndromes Version 3.2022 (Spanish - Latin America Editions)
Non-Small Cell Lung Cancer Version 7.2024 (Spanish)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Spanish)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Spanish)
Primary Cutaneous Lymphomas Version 2.2021 (Spanish)
Prostate Cancer Version 2.2021 (Spanish)
Small Cell Lung Cancer Version 3.2024 (Spanish)
T-Cell Lymphomas Version 1.2021 (Spanish)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (Spanish)
Breast Cancer Version 2.2022 (Ukrainian)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2023 (Ukrainian)
Colon Cancer Version 1.2022 (Ukrainian)
Head and Neck Cancers Version 1.2023 (Ukrainian)
Melanoma: Cutaneous Version 2.2024 (Ukrainian)
Multiple Myeloma Version 3.2023 (Ukrainian)
Myelodysplastic Syndromes Version 1.2023 (Ukrainian)
Non-Small Cell Lung Cancer Version 7.2024 (Ukrainian)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (Ukrainian)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Ukrainian)
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2023 (Ukrainian)
NCCN MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE NCCN CONTENT, THE NCCN GUIDELINES OR DERIVATIVE RESOURCES PROVIDED BY NCCN, ALL OF WHICH ARE PROVIDED "AS IS." NCCN DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NCCN DOES NOT WARRANT THE ACCURACY, APPROPRIATENESS, APPLICABILITY OR COMPLETENESS OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY DERIVATIVE RESOURCES, NOR DOES NCCN MAKE ANY REPRESENTATIONS REGARDING THE USE OR RESULTS OF THE USE OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES.
NCCN EXPLICITLY DISCLAIMS THE APPROPRIATENESS OR APPLICABILITY OF THE NCCN CONTENT, THE NCCN GUIDELINES, AND ANY DERIVATIVE RESOURCES, OR THE USE OR APPLICATION OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES, TO ANY SPECIFIC PATIENT'S CARE OR TREATMENT. ANY CLINICIAN SEEKING TO APPLY OR CONSULT THE NCCN CONTENT, THE NCCN GUIDELINES AND/OR ANY DERIVATIVE RESOURCES IS EXPECTED TO USE INDEPENDENT MEDICAL JUDGMENT IN THE CONTEXT OF THE INDIVIDUAL CLINICAL CIRCUMSTANCES TO DETERMINE ANY PATIENT'S CARE OR TREATMENT.